IN2014DN07752A - - Google Patents

Info

Publication number
IN2014DN07752A
IN2014DN07752A IN7752DEN2014A IN2014DN07752A IN 2014DN07752 A IN2014DN07752 A IN 2014DN07752A IN 7752DEN2014 A IN7752DEN2014 A IN 7752DEN2014A IN 2014DN07752 A IN2014DN07752 A IN 2014DN07752A
Authority
IN
India
Prior art keywords
microbiota
subject
altering
methods
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Lee M Kaplan
Alice P Liou
Peter J Turnbaugh
Jason L Harris
Original Assignee
Ethicon Endo Surgery Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49003107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN07752(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethicon Endo Surgery Inc, Gen Hospital Corp filed Critical Ethicon Endo Surgery Inc
Publication of IN2014DN07752A publication Critical patent/IN2014DN07752A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
IN7752DEN2014 2012-02-29 2013-02-28 IN2014DN07752A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604824P 2012-02-29 2012-02-29
PCT/US2013/028271 WO2013130773A2 (en) 2012-02-29 2013-02-28 Compositions of microbiota and methods related thereto
US13/780,284 US9173910B2 (en) 2012-02-29 2013-02-28 Compositions of microbiota and methods related thereto

Publications (1)

Publication Number Publication Date
IN2014DN07752A true IN2014DN07752A (de) 2015-05-15

Family

ID=49003107

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7752DEN2014 IN2014DN07752A (de) 2012-02-29 2013-02-28

Country Status (6)

Country Link
US (11) US9173910B2 (de)
EP (1) EP2836224A4 (de)
CN (3) CN110201003A (de)
BR (1) BR112014021388A2 (de)
IN (1) IN2014DN07752A (de)
WO (1) WO2013130773A2 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4663746A3 (de) 2010-02-01 2026-04-15 Ferring Microbiome Inc. Bakterientherapie für clostridium-difficile-colitis
IN2014DN07752A (de) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
PL2919796T3 (pl) 2012-11-19 2021-09-27 Université Catholique de Louvain Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
HK1222243A1 (zh) * 2012-12-13 2017-06-23 麦太宝根有限公司 鉴定有发生2 型糖尿病风险的人
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US9549703B2 (en) 2013-11-27 2017-01-24 Elwha Llc Devices and methods for sampling and profiling microbiota of skin
US10152529B2 (en) 2013-08-23 2018-12-11 Elwha Llc Systems and methods for generating a treatment map
US9557331B2 (en) 2013-08-23 2017-01-31 Elwha Llc Systems, methods, and devices for assessing microbiota of skin
US9526480B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US20150057623A1 (en) * 2013-08-23 2015-02-26 Elwha Llc Systems, Methods, and Devices for Delivering Treatment to a Skin Surface
US10010704B2 (en) 2013-08-23 2018-07-03 Elwha Llc Systems, methods, and devices for delivering treatment to a skin surface
US9805171B2 (en) 2013-08-23 2017-10-31 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9811641B2 (en) 2013-08-23 2017-11-07 Elwha Llc Modifying a cosmetic product based on a microbe profile
US9526450B2 (en) 2013-11-27 2016-12-27 Elwha Llc Devices and methods for profiling microbiota of skin
US9610037B2 (en) 2013-11-27 2017-04-04 Elwha Llc Systems and devices for profiling microbiota of skin
EP3134509B1 (de) * 2014-04-23 2026-01-21 Cornell University Modulation der fettspeicherung bei einer person durch veränderung der populationskonzentration von christensenellaceae im magen-darm-trakt
CN106663137B (zh) 2014-04-28 2020-07-10 耶达研究及发展有限公司 用于预测对食物的反应的方法和装置
WO2015178653A1 (ko) * 2014-05-20 2015-11-26 이화여자대학교 산학협력단 Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
US10925953B2 (en) * 2014-08-28 2021-02-23 Yale University Compositions and methods for treating an inflammatory disease or disorder
RU2717018C2 (ru) * 2014-10-02 2020-03-17 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Фармацевтические и пищевые композиции для индукции насыщения и продления чувства сытости у нуждающихся в этом субъектов
EP4529950A3 (de) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen im zusammenhang mit mikrobieller behandlung von störungen
ES2754052T3 (es) * 2015-01-26 2020-04-15 Stephanie Lynch Composiciones del caldo y su uso como prebióticos
EP3292135B1 (de) 2015-05-06 2022-09-21 Wageningen Universiteit Verwendung eines polypeptids zur durchführung von immunsignalisierung und/oder beeinflussung der darmbarrierefunktion und/oder modulation des stoffwechselstatus
AU2016271303C1 (en) 2015-06-01 2022-04-14 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
US20180153944A1 (en) * 2015-06-09 2018-06-07 Regents Of The University Of Minnesota Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
DK3347030T3 (da) 2015-09-10 2021-08-09 Univ Catholique Louvain Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
EP3442546A4 (de) * 2016-04-15 2020-03-25 National Health Research Institutes Darmflorazusammensetzungen gegen fettleibigkeit sowie herstellungsverfahren und verwendung davon
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
EP3445330B1 (de) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Verwendung von gramnegativen spezies zur behandlung von atopischer dermatitis
KR102658297B1 (ko) 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US10441612B2 (en) * 2016-08-16 2019-10-15 Taichung Veterans General Hospital Intestinal microbe therapy, composition therefor and method for preparing the same
WO2018102469A1 (en) * 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
CN107043714B (zh) * 2016-12-13 2021-03-12 广州康泽医疗科技有限公司 一种益生菌及其制备方法
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN111247254A (zh) * 2017-10-13 2020-06-05 雷柏奥提斯有限公司 微生物组健康指数
EP3723775A4 (de) 2017-12-15 2022-04-13 Solarea Bio, Inc. Mikrobielle zusammensetzungen und verfahren zur behandlung von typ-2-diabetes, fettleibigkeit und stoffwechselsyndrom
US20200345036A1 (en) * 2018-01-04 2020-11-05 White Dog Labs, Inc. Method and composition for improving health of an animal comprising cells of organism consisting of the strains within the order clostridiales
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
GB2588721A (en) 2018-05-11 2021-05-05 Forte Subsidiary Inc Compositions for the treatment of skin conditions
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
JP7558170B2 (ja) 2018-08-17 2024-09-30 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3853605A4 (de) * 2018-09-18 2022-07-06 Mcpharma Biotech Inc. Nachweis, behandlung und überwachung von mikrobiom-induzierter metabolischer dysfunktion
CN110964650B (zh) * 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
ES2763874B2 (es) * 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades
EP4010315A4 (de) * 2019-08-09 2023-11-15 The Regents of the University of California Zusammensetzungen und verfahren zur behandlung von stoffwechselkrankheiten
US20240226186A9 (en) * 2019-09-25 2024-07-11 Healthbiome Obligate anaerobic human intestinal microbe for cancer treatment, and use thereof
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
DK180598B1 (da) * 2020-02-21 2021-10-14 Sander Wilbek Theis Stivelsespropanoat anvendt som tilsætningsstof og/eller kosttilskud til mennesker til forebyggelse af overvægt og fedme
CN111388488A (zh) * 2020-04-10 2020-07-10 中国海洋大学 半乳寡糖及其衍生物在作为防治非酒精性脂肪肝药物中的应用
EP4181910A4 (de) * 2020-07-17 2024-06-05 DSM Nutritional Products, LLC Oligosaccharidzusammensetzungen und verfahren zur verwendung
BE1028339B1 (fr) 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
WO2022155443A1 (en) * 2021-01-15 2022-07-21 Yale University Compositions and methods for treating and preventing diseases or disorders using inter-species interactions
US20240268432A1 (en) 2021-07-23 2024-08-15 Universidade Católica Portuguesa - Ucp Encapsulated bacterial, methods and uses thereof
EP4436407A1 (de) 2021-11-22 2024-10-02 Solarea Bio, Inc. Verfahren und zusammensetzungen zur behandlung von muskel-skelett-erkrankungen, behandlung von entzündungen und verwaltung von menopausesymptomen
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1423823A (fr) 1964-11-20 1966-01-07 Azote Office Nat Ind Procédé de reformage catalytique et sous pression élevée des hydrocarbures pétroliers par la vapeur
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5143845A (en) 1986-09-03 1992-09-01 Toa Pharmaceutical Co., Ltd. Mixture of saccarifying lactic acid producing and butyric acid producing bacteria
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
GB9306473D0 (en) 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
ATE277739T1 (de) 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
AU6049599A (en) 1998-09-17 2000-04-03 Baxter Healthcare Sa Streptococcal c beta protein compositions
CA2354054C (en) 1998-12-11 2011-04-12 Urex Biotech, Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
ATE425244T1 (de) 1999-08-05 2009-03-15 Nestle Sa Bifidobacteria zum vorbeugen von diarrhöe infolge pathogener bakterien
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1227152A1 (de) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bakterienstamm und Genom des Bifidobacteriums
KR100845456B1 (ko) 2001-02-06 2008-07-10 소시에떼 데 프로듀이 네슬레 소시에떼아노님 젖산균 및 비피도균에 의한 내독소 결합
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
MXPA04008177A (es) 2002-02-21 2005-06-08 Nestle Sa Composicion oralmente administrable, para la fotoproteccion de la piel.
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
SE526711C2 (sv) 2003-01-31 2005-10-25 Probi Ab Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1462116A1 (de) 2003-03-29 2004-09-29 Villitech SARL Zubereitung zur Behandlung des Magen-Darm-Traktes
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050100559A1 (en) 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
EP1600060A1 (de) 2004-05-25 2005-11-30 Cognis IP Management GmbH Orale und/oder topische Zusammensetzung enthaltend Prebiotiken und Fettsäuren
AU2005257033B2 (en) 2004-06-23 2011-05-12 L'oreal Method and compositions useful for preventing and/or treating sensitive and/or dry skin
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
ITMI20041550A1 (it) 2004-07-29 2004-10-29 Proge Farm Srl Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
FR2874825B1 (fr) 2004-09-08 2006-12-08 Genibio Sarl Utilisations d'oligosaccharides prebiotiques benefiques pour la flore vaginale
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
CA2585891A1 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
PT1835021E (pt) 2004-12-28 2011-04-29 Meiji Seika Kaisha Nova estirpe que confere a um hospedeiro propriedades anti-doença e composição de células bacterianas
TW200700074A (en) 2005-03-04 2007-01-01 Calpis Co Ltd Inducer of t cell apoptosis
US20070042953A1 (en) 2005-08-16 2007-02-22 Bazan Nicolas G Antiepileptogenic complex of albumin with docosahexaenoate
FR2889958A1 (fr) 2005-08-25 2007-03-02 Lyoct Sa Lab Utilisation d'un symbiotique pour le traitement de la dermatite atopique
EP1776877A1 (de) 2005-10-21 2007-04-25 N.V. Nutricia Methode zur Förderung der Darmflora
ITRM20060237A1 (it) 2006-05-03 2007-11-04 Anabasis S R L Uso dei probiotici nella prevenzione e nel trattamento delle congiuntiviti allergiche
US20090252708A1 (en) * 2006-05-18 2009-10-08 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof
CN1850047A (zh) * 2006-06-01 2006-10-25 济南帅华医药科技有限公司 一种含β－内酰胺酶抑制剂和头孢菌素的缓释制剂及其应用
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US9644210B2 (en) 2007-02-22 2017-05-09 Jürgen Schrezenmeir Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human
US8557233B2 (en) 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
NZ580006A (en) 2007-03-28 2012-03-30 Alimentary Health Ltd Probiotic bifidobacterium strain 41387
AU2008246387B2 (en) 2007-05-03 2014-06-12 Tobias Olofsson Novel bacteria isolated from fresh honey or the honey producing tract of honey bees
TW200904340A (en) 2007-05-11 2009-02-01 Mannatech Inc Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same
EP1992351B1 (de) 2007-05-18 2016-05-11 Nestec S.A. Lactobacillus johnsonii zur vorbeugung von postoperativer Infektion
US20090010892A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Hyperlipidemia Treatment Agent
US20090010891A1 (en) 2007-07-06 2009-01-08 Toa Pharmaceutical Co., Ltd. Sepsis Treatment Agent
EP2184997A4 (de) 2007-07-31 2010-11-03 Univ New York Diagnose- und behandlungsverfahren für die charakterisierung von bakteriellen mikroorganismen bei hautkrankheiten
EP2030623A1 (de) 2007-08-17 2009-03-04 Nestec S.A. Verhinderung und/oder Behandlung von Stoffwechselerkrankungen durch Modulation der Menge der Enterobakterien
WO2009043856A2 (en) 2007-10-01 2009-04-09 University College Cork, National University Of Ireland, Cork Modulation of tissue fatty acid composition of a host by human gut bacteria
US8478544B2 (en) 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
US20090143760A1 (en) 2007-11-30 2009-06-04 Jacques Van Dam Methods, Devices, Kits and Systems for Defunctionalizing the Gallbladder
EP2072052A1 (de) 2007-12-17 2009-06-24 Nestec S.A. Verhinderung opportunistischer Infektionen bei Personen mit schwachem Immunsystem
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
EP2110028A1 (de) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum und hippocampale BDNF-Expression
EP2318513B1 (de) 2008-07-11 2012-09-19 Chr. Hansen A/S Neues probiotisches bifidobacterium longum
US8569466B2 (en) 2008-09-10 2013-10-29 Nnochiri Ekwuribe Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
AU2009315298A1 (en) 2008-11-11 2010-05-20 Alimentary Health Limited Bifidobacterium longum
WO2010129839A1 (en) 2009-05-07 2010-11-11 Tate & Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
US8784798B2 (en) 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
EP3181134B1 (de) 2009-06-19 2019-10-30 DuPont Nutrition Biosciences ApS Bifidobakterien zur behandlung von diabetes und assoziierten erkrankungen
US20150320808A1 (en) 2009-06-19 2015-11-12 Dupont Nutrition Biosciences Aps Bifidobacteria for treating cardiac conditions
US9848760B2 (en) 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
DK2459203T3 (en) 2009-07-30 2019-02-18 Dupont Nutrition Biosci Aps Lactic Acid Bacteria and Bifidobacteria for the Treatment of Endotoxemia
EP2289527B1 (de) 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum und funktionelle GI-Erkrankungen
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
DK2498626T3 (en) 2009-11-12 2015-07-13 Nestec Sa FOOD COMPOSITION TO PROMOTE GAS MICROFLORAL BALANCE AND HEALTH
EP2513292B1 (de) 2009-12-16 2017-09-06 Probiotical S.p.A. Konjugierte linolsäureproduzierende stämme probiotischer bakterien und ihre verwendung für die zubereitung einer pharmazeutischen zusammensetzung
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
EP2556835B1 (de) 2010-02-10 2015-08-05 Japan Eco-Science Co. Ltd. Mischung, auflösungslösung und pharmazeutisches mittel mit thermophilen mikroorganismen
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) * 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
KR101757504B1 (ko) 2010-06-28 2017-07-12 가부시키가이샤 야쿠르트 혼샤 경구용 피부 성상 개선제
PH12012502532A1 (en) 2010-06-30 2017-08-09 Nestec Sa Use of chicoric acid and lactic bacterium in food supplement for regulating skin pigmentation
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
US20130224164A1 (en) 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use
EP2439264B1 (de) 2010-10-11 2015-06-03 Jennewein Biotechnologie GmbH Neuartige Fucosyltransferasen und ihre Verwendungen
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
CN111518866A (zh) 2011-03-01 2020-08-11 群体创新有限责任公司 用于治疗与致病生物膜相关之病症的材料和方法
BR112013022927A2 (pt) * 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
EP2797606A4 (de) 2011-08-17 2015-09-30 MicroBiome Therapeutics LLC Zusammensetzung und verwendung einer formulierung zur erhöhung des verhältnisses von gastrointestinalen mikrobioten in pflanzenstamm-bakterioditen für mikrobioten des firmuctes-pflanzenstamms
DK2744888T3 (en) 2011-08-18 2018-03-12 Chr Hansen As Process for purifying bacterial cells
CA2851602C (en) 2011-08-30 2020-07-14 Academisch Medisch Centrum Method for preventing and/or treating insulin resistance
EP2756071B1 (de) 2011-09-14 2017-12-20 University Of Guelph Medienzusätze und verfahren zur kultivierung menschlicher anaerober magen/darm-mikroorganismen
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
US9649346B2 (en) 2011-11-02 2017-05-16 Bios Llc Probiotic stick formulation for skin maintenance and methods of use
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
CN104010648A (zh) 2011-12-07 2014-08-27 可尔必思株式会社 包含乳酸菌或其处理物的脂质代谢和/或糖代谢改善剂
IN2014DN07752A (de) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
ES2436251B1 (es) 2012-05-25 2014-10-08 Consejo Superior De Investigaciones Científicas (Csic) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas.
US20130344042A1 (en) 2012-06-20 2013-12-26 Gretchen Tanbonliong Dietary management of celiac disease and food allergy
WO2014011233A1 (en) 2012-07-09 2014-01-16 Trachtman Ira Milton Compositions and method for treatment and prophylaxis of inflammatory bowel disease
EP2885396B1 (de) 2012-08-20 2020-02-19 Chr. Hansen A/S Verfahren zur optimierung eines verfahrens zum gefriertrocknen eines bakterienhaltigen konzentrats
WO2014046804A1 (en) 2012-09-20 2014-03-27 Prothera, Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
WO2014070014A1 (en) 2012-11-01 2014-05-08 Rijksuniversiteit Groningen Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
PL2919796T3 (pl) 2012-11-19 2021-09-27 Université Catholique de Louvain Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (de) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Zusammensetzungen und verfahren
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
US11814664B2 (en) 2013-05-24 2023-11-14 Genomatica, Inc. Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate
CN105106245A (zh) 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用

Also Published As

Publication number Publication date
US20200121733A1 (en) 2020-04-23
WO2013130773A8 (en) 2014-10-16
US11590176B2 (en) 2023-02-28
CN104780932A (zh) 2015-07-15
US20170368108A1 (en) 2017-12-28
CN110201003A (zh) 2019-09-06
WO2013130773A3 (en) 2014-12-18
US20200121735A1 (en) 2020-04-23
US10729732B2 (en) 2020-08-04
US10149867B2 (en) 2018-12-11
BR112014021388A2 (pt) 2017-07-18
US20130224155A1 (en) 2013-08-29
US12048721B2 (en) 2024-07-30
US20200246395A1 (en) 2020-08-06
US20200121732A1 (en) 2020-04-23
EP2836224A4 (de) 2015-12-16
CN108771687A (zh) 2018-11-09
US20200121734A1 (en) 2020-04-23
US20200237835A1 (en) 2020-07-30
WO2013130773A2 (en) 2013-09-06
US20190046590A1 (en) 2019-02-14
US10149870B2 (en) 2018-12-11
US9173910B2 (en) 2015-11-03
US20160113971A1 (en) 2016-04-28
US20200121736A1 (en) 2020-04-23
EP2836224A2 (de) 2015-02-18

Similar Documents

Publication Publication Date Title
WO2013130773A8 (en) Compositions of microbiota and methods related thereto
HK1218560A1 (zh) 组成与方法
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EP2440210A4 (de) Verfahren zur behandlung von magen-darm-erkrankungen
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
PH12013500472A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
IN2015DN03219A (de)
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
MX2013003635A (es) Compuestos de n-heteroarilo.
MX2014013499A (es) Moduladores alostericos de receptor alfa 7 nicotinico de acetilcolina, sus derivados y usos de los mismos.
EP4316488A3 (de) Verfahren und zusammensetzungen zur behandlung von aufmerksamkeitsdefizitstörungen
WO2014030049A3 (en) Compositions comprising a single variable domain and camostat mesylate (cm)
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
WO2014194226A3 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
HK1201477A1 (en) Pharmaceutical composition of omeprazole